Compare Vanguard Sht-Term Inflation-Protected Sec Idx ETF (VTIP) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Sht-Term Inflation-Protected Sec Idx ETF vs Zoetis Inc — how do they compare? Vanguard Sht-Term Inflation-Protected Sec Idx ETF trades at $48.47 (market cap $73.20B), while Zoetis Inc trades at $74.77 (market cap $30.20B). The key difference: Vanguard Sht-Term Inflation-Protected Sec Idx ETF is far larger — about 2.4× Zoetis Inc's market cap, and Zoetis Inc pays a 2.9% dividend while Vanguard Sht-Term Inflation-Protected Sec Idx ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Vanguard Sht-Term Inflation-Protected Sec Idx ETF for 91 Days and Zoetis Inc for 70 Days on average.
| VTIP | ZTS | |
|---|---|---|
Market Cap | $73.20B | $30.20B |
Volume | 2,511,360 | 6,175,327 |
52-Week High | $50.46 | $147.53 |
52-Week Low | $48.38 | $69.09 |
Typical Hold Time | 91 Days | 70 Days |
Sector | — | Health |
Enterprise Value | — | $37.76B |
Dividend Yield | — | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VTIP trades at $48.46, showing minimal daily movement with a slight decline of 0.01%. Technical indicators present a mixed picture with bearish moving averages but bullish oscillators, including oversold RSI readings. The ETF focuses on short-term inflation-protected securities, offering protection against rising inflation while minimizing interest rate sensitivity. Recent institutional activity shows increased positions from firms like NewEdge Advisors and 55 North Private Wealth.
The outlook for VTIP remains tied to inflation dynamics and Federal Reserve policy. With inflation persisting above the 2% target, short-duration TIPS provide strategic hedging value. However, the fund faces risks from potential Fed policy shifts and real yield fluctuations. Current technical weakness suggests near-term pressure, but oversold conditions may present entry opportunities for inflation-conscious investors.
Zoetis (ZTS) trades at $74.38, up 3.96% in the last session, with a bullish technical signal and strong profitability metrics including a 71.67% gross margin and 27.69% net income margin. Recent earnings show mixed results, with a beat in Q2 2026 but a miss in Q1 2026, while Q3 2026 results are pending. The company maintains robust cash flow from operations of $2.90B in 2025 and a solid balance sheet with $1.99B in cash. Analyst consensus is a Buy with a $87.33 price target, though sentiment is tempered by near-term competitive pressures.
The outlook for ZTS is cautiously optimistic, supported by industry-leading margins and a diversified product portfolio, but faces headwinds from U.S. companion animal market weakness and increased competition. Investment opportunity lies in its undervalued P/E of 11.92 relative to growth potential, while risks include pricing erosion and volume declines. The stock's current level near resistance at $74 suggests potential for consolidation before further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vanguard Sht-Term Inflation-Protected Sec Idx ETF
The index is a market-capitalization-weighted index that includes all inflation-protected public obligations issued by the US Treasury with remaining maturities of less than 5 years. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the securities that make up the index, holding each security in approximately the same proportion as its weighting in the index.
Read more on VTIP →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
